药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
2期
177-179
,共3页
蓝晓红%周永刚%邹颖%李新立
藍曉紅%週永剛%鄒穎%李新立
람효홍%주영강%추영%리신립
临床药师%限制性心肌病%利尿剂%阿托伐他汀
臨床藥師%限製性心肌病%利尿劑%阿託伐他汀
림상약사%한제성심기병%이뇨제%아탁벌타정
Clinical pharmacist%Restrictive cardiomyopathy%Diuretics%Atorvastatin%Analysis and interven-tion
通过临床药师参与心内科1例限制性心肌病的药物治疗：针对重度水肿合并低钠、低钾、低蛋白，选用利尿剂托伐普坦。针对患者白蛋白低，改用白蛋白结合率低的普伐他汀替代阿托伐他汀（蛋白结合率>98%），降低药物的肝肾毒性。
通過臨床藥師參與心內科1例限製性心肌病的藥物治療：針對重度水腫閤併低鈉、低鉀、低蛋白，選用利尿劑託伐普坦。針對患者白蛋白低，改用白蛋白結閤率低的普伐他汀替代阿託伐他汀（蛋白結閤率>98%），降低藥物的肝腎毒性。
통과림상약사삼여심내과1례한제성심기병적약물치료：침대중도수종합병저납、저갑、저단백，선용이뇨제탁벌보탄。침대환자백단백저，개용백단백결합솔저적보벌타정체대아탁벌타정（단백결합솔>98%），강저약물적간신독성。
Clinical pharmacists implementing pharmaceutical care in drug treatment of a patient with re-strictive cardiomyopathy combined right heart failure, severe edema, hyponatremia, hypokalemia, hypoproteine-mia is reviewed in this article. Instead of furosemide, tolvaptan was recommended for its little effect on serum potassium and better security role on serum sodium. Potassium-sparing drugs should not be reused. Besides, atorvastatin was replaced with pravastatin which has lower albumin binding rate to reduce the toxicity of liver and kidney.
